ADIPOQ and metabolic syndrome: Considering the rimonabant effects on obesity, Gary-Bobo et al. investigated its impact on hepatic steatosis and the related metabolic syndrome traits (inflammation, dyslipidemia, and low plasma adiponectin levels) in obese Zucker rats.